
This study aimed to compare the cost-effectiveness of the glucagon-like peptide-1 agonists liraglutide and semaglutide in achieving weight reduction. Data from the STEP 1 trial for liraglutide and the SCALE trial for semaglutide were used. Liraglutide resulted in a 5.4% weight loss, while semaglutide led to a more substantial 12.4% weight loss. The estimated total cost of therapy during the trials was $17,585 for liraglutide and $22,878 for semaglutide. The cost needed to treat per 1% of body weight reduction was estimated at $3,256 for liraglutide and $1,845 for semaglutide. Thus, semaglutide was found to provide better value for money in terms of weight reduction compared to liraglutide.
Like
Save
Share